Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Non-Current Deffered Revenue (2016 - 2023)

Historic Non-Current Deffered Revenue for Theravance Biopharma (TBPH) over the last 11 years, with Q3 2023 value amounting to $175000.0.

  • Theravance Biopharma's Non-Current Deffered Revenue fell 1206.03% to $175000.0 in Q3 2023 from the same period last year, while for Sep 2023 it was $175000.0, marking a year-over-year decrease of 1206.03%. This contributed to the annual value of $192000.0 for FY2022, which is 3806.45% down from last year.
  • Per Theravance Biopharma's latest filing, its Non-Current Deffered Revenue stood at $175000.0 for Q3 2023, which was down 1206.03% from $181000.0 recorded in Q2 2023.
  • Theravance Biopharma's 5-year Non-Current Deffered Revenue high stood at $21.7 million for Q1 2019, and its period low was $175000.0 during Q3 2023.
  • In the last 5 years, Theravance Biopharma's Non-Current Deffered Revenue had a median value of $329000.0 in 2021 and averaged $3.7 million.
  • Within the past 5 years, the most significant YoY rise in Theravance Biopharma's Non-Current Deffered Revenue was 1091.95% (2021), while the steepest drop was 9601.69% (2021).
  • Quarter analysis of 5 years shows Theravance Biopharma's Non-Current Deffered Revenue stood at $6.8 million in 2019, then crashed by 94.85% to $348000.0 in 2020, then dropped by 10.92% to $310000.0 in 2021, then crashed by 38.06% to $192000.0 in 2022, then fell by 8.85% to $175000.0 in 2023.
  • Its Non-Current Deffered Revenue was $175000.0 in Q3 2023, compared to $181000.0 in Q2 2023 and $187000.0 in Q1 2023.